IP Library Granted Patent US 12,528,774
Granted Patent B2
US 12,528,774 · App. 17/429,722 · Granted Jan 20, 2026

Thiosemicarbazone compounds and uses thereof

Inventors: Caius G. Radu (Los Angeles, CA); Michael E. Jung (Los Angeles, CA); Daniel Sun (Los Angeles, CA); Nagichettiar Satyamurthy (Los Angeles, CA); Juno Van Valkenburgh (Los Angeles, CA); Roy Pan (Los Angeles, CA); Soumya Poddar (Los Angeles, CA)
Assignee: The Regents of the University of California
C07D217/14C07F1/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,528,774
App. No.
17/429,722
Granted
Jan 20, 2026
Kind
B2
Abstract

Provided, inter alia, are thiosemicarbazone compounds, metal complexes of thiosemicarbazone compounds, pharmaceutical compositions, and methods for treating cancer.

Claims (31)

1 . A compound of Formula (Ia), a pharmaceutically acceptable salt thereof, a metal complex thereof, or a pharmaceutically acceptable salt of a metal complex thereof:

wherein:

R 1 is unsubstituted C 1-4 alkyl;

R 2 is hydrogen or unsubstituted C 1-4 alkyl; and

R 4 , R 5 , and R 6 are each independently hydrogen, fluorine, chlorine, bromine, iodine, —NH 2 , N(C 1-4 alkyl)(C 1-4 alkyl), wherein when R 2 is H, R 4 -R 6 are all not H.

2 . The compound of claim 1 , wherein

R 1 is —CH 3 or —CH 2 CH 3 ;

R 2 is hydrogen, —CH 3 , or —CH 2 CH 3 ; and

R 4 , R 5 , and R 6 are each independently hydrogen, fluorine, chlorine, bromine, iodine, —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —N(CH 3 ) 2 , —N(CH 3 )(CH 2 CH 3 ), or —N(CH 2 CH 3 ) 2 .

3 . The compound of claim 1 , wherein

R 1 is —CH 3 or —CH 2 CH 3 ;

R 2 is hydrogen, —CH 3 , or —CH 2 CH 3 ; and

R 4 , R 5 , and R 6 are each independently hydrogen, fluorine, NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —N(CH 3 ) 2 , —N(CH 3 )(CH 2 CH 3 ), or —N(CH 2 CH 3 ) 2 .

4 . The compound of claim 1 , wherein

R 1 is —CH 3 or CH 2 CH 3 ;

R 2 is —CH 3 or CH 2 CH 3 ;

R 4 and R 6 are each independently hydrogen, fluorine, chlorine, bromine, or iodine; and

R 5 is hydrogen, NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —N(CH 3 ) 2 , —N(CH 3 )(CH 2 CH 3 ), or —N(CH 2 CH 3 ) 2 .

5 . The compound of claim 1 , wherein

R 1 is —CH 3 or CH 2 CH 3 ;

R 2 is —CH 3 or CH 2 CH 3 ;

R 4 and R 6 are each independently hydrogen or fluorine; and

R 5 is hydrogen, NH 2 , —NHCH 3 , or —NHCH 2 CH 3 .

6 . The compound of claim 1 having the structure:

7 . The compound of claim 1 having the structure:

8 . The compound of claim 1 having the structure:

9 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

10 . A composition comprising: (i) the compound of claim 1 , and (ii) copper, a copper salt, zinc, a zinc salt, cobalt, a cobalt salt, nickel, a nickel salt, magnesium, a magnesium salt, iron, an iron salt, manganese, a manganese salt, gallium, a gallium salt, germanium, a germanium salt, calcium, a calcium salt, or a combination of two or more thereof.

11 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , wherein the cancer is prostate cancer, small cell lung carcinoma, pancreatic ductal adenocarcinoma, or leukemia.

12 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

13 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 1 , wherein the cancer is prostate cancer, small cell lung carcinoma, pancreatic ductal adenocarcinoma, or leukemia.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 6, 2023
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065792/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2022
From: RADU, CAIUS G.; JUNG, MICHAEL E.; SUN, DANIEL; SATYAMURTHY, NAGICHETTIAR; VAN VALKENBURGH, JUNO; PAN, ROY; PODDAR, SOUMYA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 058892/0115 →
Continuity (2)
Provisional Application 62810160 · Feb 25, 2019
Related Publication 20220274929A1 · Sep 1, 2022
References Cited (12)
US 4269834A · Nauta · 1981 [cited by applicant]
US 6248782B1 · Elford et al. · 2001 [cited by applicant]
US 20070135464A1 · Browner et al. · 2007 [cited by applicant]
US 20130089626A1 · Pollard et al. · 2013 [cited by applicant]
US 20170100352A1 · Elford · 2017 [cited by applicant]
WO WO2016161615A1 · 2016 [cited by applicant]
Liu, Mao-Chin, et al. Journal of medicinal chemistry 38.21 (1995): 4234-4243. (Year: 1995). [cited by examiner]
French, F. A., et al. Journal of Medicinal Chemistry 17.2 (1974): 172-181. (Year: 1974). [cited by examiner]
International Search Report mailed on Jun. 9, 2020 for PCT Application No. PCT/US2020/019249, filed Feb. 21, 2020, 4 pages. [cited by applicant]
PubChem 9554793, Create Date: Oct. 23, 2006, 12 pages. [cited by applicant]
Sun, D. et al. (Mar. 25, 2019). “Evaluation of Potent Isoquinoline-Based Thiosemicarbazone Antiproliferatives Against Solid Tumor Models,” [cited by applicant]
Written Opinion mailed on Jun. 9, 2020 for PCT Application No. PCT/US2020/019249, filed Feb. 21, 2020, 7 pages. [cited by applicant]